Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Novartis
Queensland Health
US Army
Medtronic
Julphar
Mallinckrodt
Cipla
Argus Health
US Department of Justice
Federal Trade Commission

Generated: October 20, 2017

DrugPatentWatch Database Preview

Lanreotide acetate - Generic Drug Details

« Back to Dashboard

What are the generic sources for lanreotide acetate and what is the scope of lanreotide acetate freedom to operate?

Lanreotide acetate
is the generic ingredient in one branded drug marketed by Ipsen Pharma and is included in one NDA. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Lanreotide acetate has seventy-one patent family members in seventeen countries and two supplementary protection certificates in two countries.

There are three drug master file entries for lanreotide acetate. One supplier is listed for this compound.

Summary for Generic Name: lanreotide acetate

US Patents:1
Tradenames:1
Applicants:1
NDAs:1
Drug Master File Entries: see list3
Suppliers / Packagers: see list1
Bulk Api Vendors: see list14
Clinical Trials: see list1,001
Patent Applications: see list4,545
Therapeutic Class:Hormonal Agents, Suppressant (Pituitary)
Drug Prices:see low prices
DailyMed Link:lanreotide acetate at DailyMed

Pharmacology for Ingredient: lanreotide acetate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ipsen Pharma
SOMATULINE DEPOT
lanreotide acetate
SOLUTION;SUBCUTANEOUS022074-003Aug 30, 2007RXYesYes► Subscribe► Subscribe► Subscribe
Ipsen Pharma
SOMATULINE DEPOT
lanreotide acetate
SOLUTION;SUBCUTANEOUS022074-002Aug 30, 2007RXYesYes► Subscribe► Subscribe► Subscribe
Ipsen Pharma
SOMATULINE DEPOT
lanreotide acetate
SOLUTION;SUBCUTANEOUS022074-003Aug 30, 2007RXYesYes► Subscribe► Subscribe► Subscribe
Ipsen Pharma
SOMATULINE DEPOT
lanreotide acetate
SOLUTION;SUBCUTANEOUS022074-001Aug 30, 2007RXYesYes► Subscribe► SubscribeY ► Subscribe
Ipsen Pharma
SOMATULINE DEPOT
lanreotide acetate
SOLUTION;SUBCUTANEOUS022074-001Aug 30, 2007RXYesYes► Subscribe► Subscribe► Subscribe
Ipsen Pharma
SOMATULINE DEPOT
lanreotide acetate
SOLUTION;SUBCUTANEOUS022074-003Aug 30, 2007RXYesYes► Subscribe► SubscribeY ► Subscribe
Ipsen Pharma
SOMATULINE DEPOT
lanreotide acetate
SOLUTION;SUBCUTANEOUS022074-002Aug 30, 2007RXYesYes► Subscribe► SubscribeY ► Subscribe
Ipsen Pharma
SOMATULINE DEPOT
lanreotide acetate
SOLUTION;SUBCUTANEOUS022074-001Aug 30, 2007RXYesYes► Subscribe► Subscribe► Subscribe
Ipsen Pharma
SOMATULINE DEPOT
lanreotide acetate
SOLUTION;SUBCUTANEOUS022074-002Aug 30, 2007RXYesYes► Subscribe► Subscribe► Subscribe
Ipsen Pharma
SOMATULINE DEPOT
lanreotide acetate
SOLUTION;SUBCUTANEOUS022074-001Aug 30, 2007RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: lanreotide acetate

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,142,972 Method and apparatus for the delivery of elongate solid drug compositions► Subscribe
5,582,591 Delivery of solid drug compositions► Subscribe
5,660,846 Methods and apparatus for the delivery of solid drug compositions► Subscribe
5,837,276 Apparatus for the delivery of elongate solid drug compositions► Subscribe
6,306,420 Methods and apparatus for the delivery of solid drug compositions► Subscribe
5,616,123 Delivery of solid drug compositions► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: lanreotide acetate

Country Document Number Estimated Expiration
Denmark0779805► Subscribe
South Africa9601904► Subscribe
Austria378082► Subscribe
Greece3032947► Subscribe
European Patent Office0778767► Subscribe
Hong Kong1067870► Subscribe
World Intellectual Property Organization (WIPO)9607440► Subscribe
Portugal1498150► Subscribe
Austria306906► Subscribe
China1846669► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: LANREOTIDE ACETATE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2002 00032Denmark► Subscribe
037Luxembourg► Subscribe91037, EXPIRES: 20160511
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Moodys
Fuji
Farmers Insurance
Cerilliant
Chubb
Queensland Health
AstraZeneca
UBS
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot